Abstract:Objective: To identify the genetic defect causing dominant X-linked ALS and ALS/dementia, and characterize the functional and pathological determinants. Background Most cases of ALS are sporadic but about 5-10% are familial. Mutations in SOD1, TDP43 and FUS account for approximately 30% of classic familial ALS. The causes of the remaining cases of familial ALS and of the vast majority of sporadic ALS are unknown. Despite extensive studies of previously identified ALS-causing genes, the pathogenic mechanism underlying motor-neuron degeneration in ALS remains largely obscure. Dementia, usually of the frontotemporal lobar type, may occur in some ALS cases. It is unclear whether ALS and dementia share common aetiology and pathogenesis in ALS/dementia. More than a decade ago, we had linked a large ALS family to the pericentric region of the X chromosome. Design/Methods: Detailed mapping was done with dense microsatellite markers and Illumina Sentrix HumanHap300 Genotyping BeadChip. Candidate genes were sequenced using Beckman Coulter CEQ 8000 DNA analysis system. Immunohistochemistry and light and confocal microscopy were performed according to standard protocols. Neuro2a and SHSY-5Y cells were transiently co-transfected with a ubiquitin-proteasome system (UPS) reporter plasmid (Ub-G76V-GFP) and pIRES2-DsRed2 dual expression vectors containing either wildtype or mutant UBQLN2 and analyzed using a MoFlo cell sorter and Summit software. Results: We show mutations of ubiquilin2, a ubiquitin-like protein, in five families with ALS and ALS/dementia. We also show that inclusions containing ubiquilin2 are a common pathological feature in a wide spectrum of ALS and ALS/dementia. Functional studies indicate an impairment of ubiquitin-mediated proteasomal degradation in cells expressing mutant ubiquilin2. Conclusions: These data provide evidence for an impairment of protein turnover in the pathogenesis of ALS and ALS/dementia. Further elucidation of these processes may be central to the understanding of pathogenic pathways. These pathways should provide novel molecular targets for the design of rational therapies for these disorders. Supported by: The National Institute of Neurological Disorders and Stroke (NS050641), the Les Turner ALS Foundation, the Vena E. Schaff ALS Research Fund, the Harold Post Research Professorship, the Herbert and Florence C. Wenske Foundation, the David C. Asselin MD Memorial Fund, the Help America Foundation and the Les Turner ALS Foundation/Herbert C. Wenske Foundation Professorship. F.F. has support from NIH (T32 AG20506). K.A. is a postdoctoral fellow of the Blazeman Foundation for ALS. G.H.G. received travel funds from MND Scotland. Disclosure: Dr. Fecto has nothing to disclose. Dr. Deng has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Hong has nothing to disclose. Dr. Boycott has nothing to disclose. Dr. Gorrie has nothing to disclose. Dr. Siddique has nothing to disclose. Dr. Yang has nothing to disclose. Dr. Shi has nothing to disclose. Dr. Zhai has nothing to disclose. Dr. Jiang has nothing to disclose. Dr. Hirano has nothing to disclose. Dr. Rampersaud has nothing to disclose. Dr. Jansen has nothing to disclose. Dr. Donkervoort has nothing to disclose. Dr. Bigio has nothing to disclose. Dr. Brooks has received personal compensation for activities with Avanir Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Biogen Idec, Genentech, Inc., and Teva Neuroscience. Dr. Brooks has received research support from Avanir Pharmaceuticals, Biogen Idec, NINDS, Novartis, and Teva Neuroscience. Dr. Ajroud has nothing to disclose. Dr. Sufit has nothing to disclose. Dr. Haines has nothing to disclose. Dr. Mugnaini has nothing to disclose. Dr. Pericak-Vance has nothing to disclose. Dr. Siddique has nothing to disclose.

Mutational and Transcriptional Profiling of Cuproptosis-Associated Genes in Amyotrophic Lateral Sclerosis

Exploring the cuproptosis-related molecular clusters in the peripheral blood of patients with amyotrophic lateral sclerosis

Clinical Features and Cu/Zn Superoxide Dismutase Gene Mutations in Two Mainland Chinese Families with Amyotrophic Lateral Sclerosis

Screening and validating genes associated with cuproptosis in systemic lupus erythematosus by expression profiling combined with machine learning

Unbiased Label-Free Quantitative Proteomics of Cells Expressing Amyotrophic Lateral Sclerosis (ALS) Mutations in CCNF Reveals Activation of the Apoptosis Pathway: A Workflow to Screen Pathogenic Gene Mutations

Machine Learning Screening for Parkinson’s Disease-Related Cuproptosis-Related Typing Development and Validation and Exploration of Personalized Drugs for Cuproptosis Genes

Identification of Regulatory Factors and Prognostic Markers in Amyotrophic Lateral Sclerosis

Mutation Screening of SPTLC1 and SPTLC2 in Amyotrophic Lateral Sclerosis

Functional identification of protocadherin alpha 9 (PCDHA9) as a candidate causative gene for amyotrophic lateral sclerosis

A Genome-wide Expression Association Analysis Identifies Genes and Pathways Associated with Amyotrophic Lateral Sclerosis

Mutation Spectrum of Chinese Patients with Familial and Sporadic Amyotrophic Lateral Sclerosis

Single-cell transcriptional landscape of peripheral immunity and biomarkers for human sporadic amyotrophic lateral sclerosis patients

Gene expression profiles and protein-protein interaction networks in amyotrophic lateral sclerosis patients with C9orf72 mutation

Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD

UBQLN2 Mutations in ALS and ALS/Dementia: A Genetic, Functional and Histopathological Analysis (S05.006)

Abnormal Brain Protein Abundance and Cross-tissue mRNA Expression in Amyotrophic Lateral Sclerosis

A Genome-Wide Association Study Combining Pathway Analysis for Typical Sporadic Amyotrophic Lateral Sclerosis in Chinese Han Populations

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

Integrated temporal profiling of iPSCs-derived motor neurons from ALS patients carrying C9orf72, FUS, TARDBP, and SOD1 mutations

PCDHA9 as a candidate gene for amyotrophic lateral sclerosis

Novel and Recurrent Mutations in a Cohort of Chinese Patients with Young-Onset Amyotrophic Lateral Sclerosis